Idera Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1989-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.aceragen.com
Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-10-07
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Idera Pharmaceuticals, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT00990938
Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma
- First Posted Date
- 2008-08-06
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Idera Pharmaceuticals, Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT00729053
- Locations
- 🇺🇸
Georgetown University, Lombardi Cancer Center, Washington, District of Columbia, United States
Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients
- First Posted Date
- 2008-08-06
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Idera Pharmaceuticals, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT00728936
- Locations
- 🇺🇸
Henry Ford Med Ctr- Columbus, Novi, Michigan, United States
🇵🇷Fundacion de Investigacion de Diego, Santurce, Puerto Rico
🇺🇸University of Colorado Hospital, Aurora, Colorado, United States
© Copyright 2024. All Rights Reserved by MedPath